Gilead Sciences, Inc., et al v. TEVA Pharmaceuticals Industries Limited et al > Summary
Court Case Number 1:10-cv-01798
Filing Date Mar 5, 2010
Termination Date May 26, 2010
Court New York Southern District Court
Status Dismissed - Other
Defendant
Plaintiff Attorneys
10Emory University
Attorney Name: Christopher P. Borello
Venable
Gilead Sciences
Attorney Name: Christopher P. Borello
Venable
Emory University
Attorney Name: Nicholas M. Cannella
Venable
Gilead Sciences
Attorney Name: Nicholas M. Cannella
Venable
Emory University
Attorney Name: Michael E. Furrow
Venable
Gilead Sciences
Attorney Name: Michael E. Furrow
Venable
Emory University
Attorney Name: Vishal C. Gupta
Venable
Gilead Sciences
Attorney Name: Vishal C. Gupta
Venable
Emory University
Attorney Name: Colleen Tracy James
Venable
Gilead Sciences
Attorney Name: Colleen Tracy James
Venable
Defendant Attorneys
10Teva Pharmaceuticals
Attorney Name: Michael J. Freno
Seed Intellectual Property Law Group
Teva Pharmaceuticals
Attorney Name: James Wright Galbraith
Hunton Andrews Kurth
Teva Pharmaceuticals
Attorney Name: James Wright Galbraith
Hunton Andrews Kurth
Teva Pharmaceuticals
Attorney Name: Elizabeth A. Gardner
Hunton Andrews Kurth
Teva Pharmaceuticals
Attorney Name: Elizabeth A. Gardner
Hunton Andrews Kurth
Teva Pharmaceuticals
Attorney Name: Maria Luisa Palmese
Hunton Andrews Kurth
Teva Pharmaceuticals
Attorney Name: Maria Luisa Palmese
Hunton Andrews Kurth
Teva Pharmaceuticals
Attorney Name: Karen C. Shen
Hunton Andrews Kurth
Teva Pharmaceuticals
Attorney Name: Karen C. Shen
Hunton Andrews Kurth
Cause
35:271 Patent Infringement
Related Patents
| Doc No | Title | Issue date |
|---|---|---|
| 06043230 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability | Mar 28, 2000 |
| 05977089 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability | Nov 2, 1999 |
| 05935946 | Nucleotide analog composition and synthesis method | Aug 10, 1999 |
| 05922695 | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability | Jul 13, 1999 |
